Richard A Gabel

Title: Richard A. Gabel: Innovator in Peptide Synthesis and Organic Chemistry

Introduction

Richard A. Gabel is a notable inventor based in Louisville, Colorado. He has made significant contributions to the field of peptide synthesis and organic chemistry, holding a total of 2 patents. His work focuses on innovative techniques that enhance the preparation of biologically relevant compounds.

Latest Patents

Gabel's latest patents include groundbreaking inventions in the synthesis of insulinotropic peptides and derivatives of unsaturated, cyclic organic acids. The first patent, titled "Insulinotropic peptide synthesis using solid and solution phase combination techniques," describes a hybrid approach that combines solid phase and solution phase chemistry. This method allows for the efficient synthesis of insulinotropic peptides, such as Exenatide(1-39), by utilizing pseudoproline to facilitate the process.

The second patent, "Derivatives of unsaturated, cyclic organic acids," focuses on the preparation of various derivatives of organic acids, including shikimic acid. This invention outlines methods for creating functionalized derivatives that can be used in the synthesis of important pharmaceuticals, such as Oseltamivir Phosphate.

Career Highlights

Throughout his career, Richard A. Gabel has worked with prominent companies in the pharmaceutical industry. He has been associated with Roche Palo Alto LLC and Corden Pharma Colorado, Inc., where he has contributed to various research and development projects. His expertise in peptide synthesis and organic chemistry has made him a valuable asset in these organizations.

Collaborations

Gabel has collaborated with several professionals in his field, including Paul Adam Bury and John Edward Crider. These collaborations have likely enriched his research and contributed to the advancement of his innovative work.

Conclusion

Richard A. Gabel is a distinguished inventor whose contributions to peptide synthesis and organic chemistry have had a significant impact on the pharmaceutical industry. His innovative patents and collaborations reflect his commitment to advancing scientific knowledge and technology.